FDA panel to discuss Remoxy

Durect Corp. (NASDAQ:DRRX) and Pain Therapeutics Inc. (NASDAQ:PTIE) said FDA's Anesthetic and Analgesic Drug Products and Drug Safety and Risk Management advisory committees will meet Aug. 5 to discuss Pain's NDA for Remoxy oxycodone to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Its PDUFA date is Sept. 25. ...